'Replacement' Director/PDMR Shareholding

    RNS Number : 5631B
  Research Pharmaceutical SRV, Inc
  18 August 2008
   

    This announcement replaces the previous RNS announcement released at 14:57 on 18 August 2008 under reference 5500B, which incorrectly
stated the final vesting date as August 15, 2021. The correct date should be August 15, 2018. The full corrected text of the announcement
appears below.


    ReSearch Pharmaceutical Services, Inc.
    Grant of Options

    ReSearch Pharmaceutical Services, Inc.("RPS" or the "Company"), a leading provider of integrated clinical development outsourcing
solutions to the bio-pharmaceutical industry, is pleased to announce that is granted stock options (the "Grant") over a total of 10,000
shares of common stock to certain directors of the Company on August 15, 2008.

    The stock options are exercisable at $3.70 per share being the most recent executed trade as of the date of the grant August 15, 2008. 
The options will vest over the next three calendar years, with one third of the options being made available to the option holder each
successive year.  The fully vested options are exercisable at any time between August 15, 2011 and August 15, 2018 being a period of between
three and ten years from the date of grant.

    The Grant has been made to the following RPS directors:

 Jack Dean, Non-executive Director     5,000
 Warren Myers, Non-executive Director  5,000

    Following the Grant each of Jack Dean and Warren Myers hold options totaling 5,000 shares each and are not holding any other share
amounts of RPS common stock.

    For further information please contact:
 ReSearch Pharmaceutical Services, Inc.:  [phone]
 Daniel M. Perlman, Chairman & Chief
 Executive Officer
 Steven Bell, Chief Financial Officer

 Nominated Adviser and UK Broker:         [phone]
 Arbuthnot Securities Limited
 James Steel/Richard Tulloch


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
RDSEVLFFVVBBBBK